Expression library immunization to discover and improve vaccine antigens

Immunological Reviews

Volumn 199, Issue , 2004, Pages 68-83

  Barry, Michael A ^a,b,c   Howell, Dasein P G ^b   Andersson, Helen A ^b   Chen, Jiang Li ^a   Singh, Rana A K ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS VACCINE;

ANTIGEN EXPRESSION; GENE LIBRARY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNIZATION; IMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SCREENING; VACCINATION;

ANTIGEN PRESENTATION; ANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLONING, MOLECULAR; GENOMIC LIBRARY; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNIZATION; UBIQUITIN; VACCINES, DNA;

EID: 2942611154     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00143.x     Document Type: Review

References (101)

1. Sanford JC, Klein TM, Wolf ED, Allen N. Delivery of substances into cells and tissues using a particle bombardment process. J Part Sci Technol 1987;5:27-37.
2. McCabe DE, Swain WF, Martinell BJ, Christou P. Stable transformation of soybean (Glycine max) by particle acceleration. Biotechnology 1988;6: 923-926.
3. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990;87:9568-9572.
4. Johnston SA, Riedy M, DeVit MJ, Sanford JC, McElligott S, Williams RS. Biolistic transformation of animal tissue. In Vitro Cell Dev Biol Anim 1991;27P:11-14.
5. Wolff JA, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
6. Acsadi G, et al. Direct gene transfer and expression into rat heart in vivo. New Biol 1991;3:71-81.
7. Wolff JA, Williams P, Acsadi G, Jiao S, Jani A, Chong W. Conditions affecting direct gene transfer into rodent muscle in vivo. Biotechniques 1991;11:474-485.
8. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992;1:363-369.
9. Barry MA, Singh RAK, Andersson HA. Gene Gun Technologies: Applications for Gene Therapy and Genetic Immunization. In: Smyth-Templeton N, ed. Gene Therapy: Therapeutic Mechanisms and Strategies. New York, NY: Marcel Dekker Inc., 2003.
10. Tang D, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152-154.
11. Ulmex JB, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749.
12. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993;90:11478-11482.
13. Davis HL, Michel M-L, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum Mol Genet 1993;2:1847-1851.
14. Conry RM et al. Immune response to a carcinoembryonic antigen polynucleotide vaccine. Cancer Res 1994;54:1164-1168.
15. Han R, Cladel NM, Reed CA, Peng X, Christensen ND. Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes. J Virol 1999;73:7039-7043.
16. Chen Y, Takimoto T, Liu L, Surman S, Woodland DL. DNA vaccination as a tool to identify subdominant CD8 T cell epitopes. Vaccine 1999;18:720-727.
17. Barry MA, Lai WC, Johnston SA. Protection against mycoplasma infection using expression library immunization: A general approach to vaccine development. Nature 1995;377:632-635.
18. Johnston SA, Sykes KF, Barry MA. DNA-based vaccines: Extending the technology. In: Levine MM, ed. New Generation Vaccines. New York: Marcel Dekker Inc., 1997: 1-8.
19. Sykes KF, Johnston SA. Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses. DNA Cell Biol 1999;18:521-531.
20. Singh RA, Wu L, Barry MA. Generation of genome-wide CD8 T cell responses in HLA-A*0201 transgenic mice by an HIV-1 ubiquitin expression library immunization vaccine. J Immunol 2002;168:379-391.
21. Sykes KF, Lewis MG, Squires B, Johnston SA. Evaluation of SIV library vaccines with genetic cytokines in a macaque challenge. Vaccine 2002;20:2382-2395.
22. Locher CP, Sykes KF, Blackbourn DJ, Johnston SA. Immune responses in baboons vaccinated with HIV-2 genetic expression libraries. J Med Primatol 2002;31:323-329.
23. Fralish BH, Tarleton RL. Genetic immunization with LYT1 or a pool of transsialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine 2003;21:3070-3080.
24. Singh RAK, Barry MA. HIV-1 genetic vaccines: Comparison of HLA-A*0201-restricted CD8 T cell responses by wild-type, codon-optimized, and an Expression Library Immunization (ELI) gag-pol vaccine. J Immunol 2004 (in press).
25. Talaat, AM, Lyons, R, Johnston, SA. A combination vaccine confers full protection against co-infections with influenza, herpes simplex and respiratory syncytial viruses. Vaccine 2001;20:538-544.
26. Alberti E, et al. Specific cellular and humoral immune response in Balb/c mice immunised with an expression genomic library of Trypanosoma cruzi. Vaccine 1998;16:608-612.
27. Brayton KA, Vogel SW, Allsopp BA. Expression library immunization to identify protective antigens from Cowdria ruminantium. In: Jongejan F, Goff W Camus E, eds. Tropical Veterinary Medicine. New York: New York Academy of Sciences, 1998: 369-371.
28. Manoutcharian K, Terrazas LI, Gevorkian G, Govezensky T. Protection against murine cysticercosis using cDNA expression library immunization. Immunol Lett 1998;62:131-136.
29. Manoutcharian K, Terrazas LI, Gevorkian G, Govezensky T. DNA pulsed macrophage-mediated cDNA expression library immunization in vaccine development. Vaccine 1999;18:389-391.
30. Drew DR, Lightowlers M, Strugnell RA. Vaccination with plasmid DNA expressing antigen from genomic or cDNA gene forms induces equivalent humoral immune responses. Vaccine 1999;18:692-702.
31. Piedrafita D, Xu DM, Hunter D, Harrison RA, Liew FY. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major. J Immunol 1999;163:1467-1472.
32. Melby PC, et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractious of a cDNA expression library. Infect Immun 2000;68:5595-5602.
33. Smooker PM, Setiady YY, Rainczuk A, Spithill TW. Expression library immunization protects mice against a challenge with virulent rodent malaria. Vaccine 2000;18:2533-2540.
34. Moore RJ, Lenghaus C, Sheedy SA, Doran TJ. Improved vectors for expression library immunization - application to Mycoplasma hyopneumoniae infection in pigs. Vaccine 2001;20:115-120.
35. Almazan C, Kocan KM, Bergman DK, Garcia-Garcia JC, Blouin EF, de la Fuente J. Identification of protective antigens for the control of Ixodes scapularis infestations using cDNA expression library immunization. Vaccine 2003;21:1492-1501.
36. Delcayre A, et al. A genome-based functional screening approach to vaccine development that combines in vitro assays and DNA immunization. Vaccine 2003;21:3259-3264.
37. Foy BD, et al. Induction of mosquitocidal activity in mice immunized with Anopheles gambiae midgut cDNA. Infect Immun 2003;71:2032-2040.
38. Rainczuk A, Scorza T, Smooker PM, Spithill TW. Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors. Infect Immun 2003;71: 4506-4515.
39. Ivey FD, Magee DM, Woitaske MD, Johnston SA, Cox RA. Identification of a protective antigen of Coccidioides immitis by expression library immunization. Vaccine 2003;21:4359-4367.
40. Barry MA, Lai WC, Johnston SA. Protection against mycoplasma infection using expression-library immunization. Nature 1995;377:632-635.
41. Kozak M. Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes. Nucleic Acids Res 1981;9:5233-5262.
42. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998;72:1497-1503.
43. Wu L, Barry MA. Fusion protein vectors to increase protein production and evaluate the immunogenicity of genetic vaccines. Mol Ther 2000;2:288-297.
44. Johnson ES, Bartel B, Seufert W, Varshavsky A. Ubiquitin as a degradation signal. EMBO J 1992;11:497-505.
45. Rodriguez F, Zhang J, Whitton JL. DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997;71:8497-8503.
46. Wu Y, Kipps TJ. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J Immunol 1997;159: 6037-6043.
47. Rodriguez F, et al. DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol 1998;72:5174-5181.
48. Delogu G, Howard A, Collins FM, Morris SL. DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity. Infect Immun 2000;68:3097-3102.
49. Liu WJ, Zhao KN, Gao FG, Leggatt GR, Fernando GJ, Frazer IH. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 2001;20:862-869.
50. + T cell recognition. J Biol Chem 2001;276:33353-33360.
51. Velders MP, et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J Immunol 2001;166:5366-5373.
52. Leachman SA, et al. Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol 2002;76:7616-7624.
53. Ye M, Morello CS, Spector DH. Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge. J Virol 2002;76:2100-2112.
54. Rombel IT, Sykes KF, Rayner S, Johnston SA. ORF-FINDER: a vector for high-throughput gene identification. Gene 2002;282:33-41.
55. Sykes KF, Johnston SA. Linear expression elements: a rapid, in vivo, method to screen for gene functions. Nat Biotechnol 1999;17:355-359.
56. Huffman SL, Rogers WO, Carucci DJ, Venter JC. From genomics to vaccines: malaria as a mode system. Nat Med 1998;4:1351-1353 (comment).
57. Johnston SA, Barry MA. Genetic to genomic vaccination. Vaccine 1996;15:808-809.
58. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999;284:1351-1354.
59. Haas J, Park EC, Seed B. Codon usage limitation in the expression of HIV-1 envelope glycoprotein. Curr Biol 1996;6:315-324.
60. Narum DL, et al. Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun 2001;69:7250-7253.
61. Gaucher D, Chadee K. Construction and immunogenicity of a codon-optimized Entamoeba histolytica Gal-lectin-based DNA vaccine. Vaccine 2002;20:3244.
62. Barouch DH, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000;290:486-492.
63. Lu S, et al. Immunogenicity of DNA vaccine expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 1998;14:151-155.
64. + T cell responses to EBV EBNA1: HLA Class I Presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997;7:791-802.
65. Hengel H, et al. A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity 1997;6:623-632.
66. Tobery TW, Siliciano RF. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization. J Exp Med 1997;185:909-920.
67. Vidalin O, Tanaka E, Spengler U, Trepo C, Inchauspe G. Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol 1999;18:611-621.
68. Deng H, et al. A modified DNA vaccine to p53 induces protective immunity to challenge with a chemically induced sarcoma cell line. Cell Immunol 2002;215:20-31.
69. Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 1986;234:179-186.
70. Johnson ES, Ma PC, Ota IM, Varshavsky A. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem 1995;270:17442-17456.
71. Suzuki T, Varshavsky A. Degradation signals in the lysine-asparagine sequence space. EMBO J 1999;18:6017-6026.
72. Andersson HA, Barry MA. Evaluation of proteasome targeting in mammalian cells by the N-end rule and ubiquitin fusion degradation pathway. J Immunol 2004 (in press).
73. Fu TM, Guan L, Friedman A, Ulmer JB, Liu MA, Donnelly JJ. Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens. Vaccine 1998;16:1711-1717.
74. Schubert U, Anton LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000;404:770-774.
75. Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998;392:408-410.
76. Xiong S, Gerloni M, Zanetti M. Engineering vaccines with heterologous B and T cell epitopes using immunoglobulin genes. Nat Biotechnol 1997;15:882-886.
77. You Z, Hester J, Rollins L, Spagnoli GC, van der Bruggen P, Chen SY. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. Cancer Res 2001;61: 197-205.
78. Rowell JF, et al. Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells. J Immunol 1995;155:1818-1828.
79. Wu TC, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci USA 1995;92: 11671-11675.
80. Ji H, et al. Targeting human papillomavirus type 16 E7 to die endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papulomavirus type 16 E7-expressing tumors. Hum Gene Ther 1999;10:2727-2740.
81. Chen CH, Ji H, Suh KW, Choti MA, Pardoll DM, Wu TC. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther 1999;6:1972-1981.
82. Chen CH, Suh KW, Ji H, Choti MA, Pardoll DM, Wu TC. Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver. J Hepatol 2000;33:91-98.
83. Cheng WF, et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther 2001;12:235-252.
84. Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV 16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001;281:231-238.
85. Chen CH, et al. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Ther 2001;8:128-138.
86. Brinster C, et al. Different hepatitis C virus nonstructural protein 3 (Ns3)-DNA-expressing vaccines induce in HLA-A2.1 transgenic mice stable cytotoxic T lymphocytes that target one major epitope. Hepatology 2001;34:1206-1217.
87. Raviprakash K, et al. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology 2001;290:74-82.
88. Uchiyama H, et al. Endosomal/lysosomal targeting of a single helper T-cell epitope of an intracellular bacterium by DNA immunisation induces a specific T-cell subset and partial protective immunity in vivo. FEMS Microbiol Lett 2002;216:91-97.
89. Smahel M, Sima P, Ludvikova V, Marinov I, Pokorna D, Vonka V. Immunisation with modified HPV 16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 2003;21:1125-1136.
90. Lu Y, et al. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. Vaccine 2003;21:2178-2189.
91. Kim TW, et al. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol 2003;171:2970-2976.
92. Marques ET Jr., et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 2003;278:37926-37936.
93. van Bergen J, Camps M, Offringa R, Melief CJ, Ossendorp F, Koning F. Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide. Cancer Res 2000;60:6427-6433.
94. van Bergen J, Schoenberger SP, Verreck F, Amons R, Offringa R, Koning F. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP. Proc Natl Acad Sci USA 1997;94:7499-7502.
95. Wang RF. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol Rev 2002;188:65-80.
96. Ulmer JB, Liu MA. ELI's coming: Expression library immunization and vaccine antigen discovery. Trends Microbiol 1996;4:169-170.
97. Johnston SA, Barry MA, Lai WC. Response from Johnston, Barry, and Lai to: ELI's coming: expression library immunization and vaccine antigen discovery. Trends Microbiol 1996;4:170-171.
98. Klenerman P, Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 1998;394:482-485.
99. Jameson SC. T cell receptor antagonism in vivo, at last. Proc Natl Acad Sci USA 1998;95: 14001-14002.
100. Jameson SC, Carbone FR, Bevan MJ. Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells. J Exp Med 1993;177:1541-1550.
101. Singh RA, Wu L, Barry MA. The role of T cell antagonism and original antigenic sin in genetic immunization. J Immunol 2002;169:6779-6786.